AETHLON MEDICAL INC — Form S-1/A
Filed July 1, 2026 · analyzed by the Registration Agent
S-1/A
— Neutral
significance 72/100
What the filing says
Aethlon Medical, Inc. (NASDAQ: AEMD), a $5.7M market cap medical device company, filed Amendment No. 1 to its Form S-1 registration statement on July 1, 2026, for a best-efforts offering of up to 4.7M shares of common stock at $0.85/share plus accompanying common warrants (exercisable at $0.85/share for 5 years post-stockholder approval), plus pre-funded warrants at $0.849 each, targeting $4M gross proceeds. Maxim Group LLC is the exclusive placement agent receiving 6.5% cash fee ($260K) plus warrants to purchase 188,235 shares (4% of issued shares). No minimum closing condition; offering terminates within one year. Company must hold stockholder meeting by October 1, 2026 to approve warrant exercises.
Why this rating
Capital raise of $4M (~70% of market cap) is material and dilutive; warrant overhang creates future dilution risk, but best-efforts structure and no minimum threshold limit upside. Standard biotech financing with moderate execution risk.
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.